Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy—Lung-MAP S1800A

Published in Journal of Clinical Oncology · View the paper (DOI)

A Phase II clinical trial found that an immunotherapy drug combination extended the lives of patients with non-small cell lung cancer, improving survival by 14.5 months compared to standard care therapy. The treatment also reduced chemotherapy use and side effects.

Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy—Lung-MAP S1800A

Coverage from 2 institutions